Última actualización 4 de julio de 2026
Key finding
Participants in the tirzepatide-pooled group had statistically significant improved scores across all SF-36v2 domains compared with insulin lispro-treated participants (p < 0.05).
This study compared tirzepatide and insulin lispro in patients with type 2 diabetes, finding significant improvements in health-related quality of life with tirzepatide.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared tirzepatide and insulin lispro in patients with type 2 diabetes, finding significant improvements in health-related quality of life with tirzepatide.
Improving health-related quality of life is crucial for patients with chronic conditions like type 2 diabetes. The significant benefits observed with tirzepatide could lead to better adherence to treatment and improved overall health outcomes, making it a valuable option for diabetes management.
The study's sample size and demographic diversity may limit generalizability. Long-term effects of tirzepatide on quality of life were not assessed. Potential biases in self-reported measures could affect outcome validity.
Published in
Publication details and source links for this paper.
Kristina SB, Jiat LP, Laura FL, et al. Tirzepatide versus Insulin Lispro in Patients with Type 2 Diabetes: Health-Related Quality of Life Outcomes. Diabetes Therapy. 2024;15(9):2039-2059. doi:10.1007/s13300-024-01620-8
Tirzepatide improved health-related quality of life scores across all SF-36v2 domains (p < 0.05).
Significant enhancements in general health (5.2 score increase, p = 0.001) and vitality (6.1 score increase, p = 0.003) were noted.
Improvements in mental health scores (5.5 score increase, p = 0.004) and ability to perform daily activities were also significant.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Tirzepatide and Activities of daily living, Health-related quality of life, Mental health, and 3 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
6
Evidence pairs
50
Related studies
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Relación de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Tirzepatide → Activities of daily living
Tirzepatide → Activities of daily living
Tirzepatide → Health-related quality of life
Tirzepatide → Health-related quality of life
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Activities of Daily Living, GLP-1 Receptor Agonists and Quality of Life Outcomes.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring Activities of Daily Living
Measures Activities of Daily Living as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring Quality of Life Outcomes
Measures Quality of Life Outcomes as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists may improve Activities of Daily Living.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Activities of daily living
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
GLP-1 Receptor Agonists appears to improve Mental Health.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Mental health
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
GLP-1 Receptor Agonists appears to improve Quality of Life Outcomes.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Health-related quality of life
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Quality of life
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Tirzepatide appears to improve Self-Perceptions Impact.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Self-Perceptions Impact
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
